QV Bioelectronics is developing Electric Field Therapy, which utilizes specific electrical frequencies to disrupt the growth cycles of glioblastoma cells, a highly treatment-resistant brain cancer. Their GRACE device aims to deliver continuous electric field therapy directly to tumor resection margins, targeting the area where most glioblastoma recurrences occur, thereby improving patient survival and quality of life.
Funding
$4.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IUFounders
Product
Problem
Glioblastoma, a highly aggressive brain cancer, has limited effective treatment options and a high recurrence rate, leading to poor patient survival and quality of life. Current treatments often fail to prevent tumor regrowth at the resection margins following surgery. Innovation in glioblastoma treatment has lagged behind other cancer treatments for decades.
Solution
QV Bioelectronics is developing GRACE (Glioma Resection Advanced Cavity Electric field therapy), an implanted device designed to deliver continuous Electric Field Therapy (EFT) directly to the tumor resection margins after surgery. EFT utilizes specific electrical frequencies to disrupt glioblastoma cell growth cycles, slowing down tumor growth. By targeting the area where recurrence is most common, GRACE aims to improve patient survival rates and quality of life by providing continuous, localized therapy while minimizing the impact on the patient's overall well-being. The device is intended to provide a more effective and targeted approach to managing glioblastoma recurrence compared to existing treatments.
Target Audience
The primary target audience includes glioblastoma patients undergoing surgery and their neuro-oncologists seeking to improve treatment outcomes and reduce recurrence rates.
Features
- Implantable device for direct delivery of Electric Field Therapy to tumor resection margins.
- Utilizes specific electrical frequencies to disrupt glioblastoma cell growth.
- Designed for continuous therapy to prevent tumor regrowth.
- Aims to minimize impact on patient quality of life compared to existing treatments.